The Medicine Maker examines GLP-1 manufacturing capacity squeeze
Trade publication looks at production constraints facing makers of incretin drugs amid sustained global demand.
TR
By Tom Reyes · Markets Editor
Sep 16 09:04 ETSource: The Medicine Maker
The wire
- 01The Medicine Maker published a feature on capacity constraints in GLP-1 manufacturing.
- 02Fill-finish and API capacity remain a limiting factor for supply of obesity and diabetes drugs.
- 03The item does not identify specific manufacturers, sites or expansion timelines.
From the source
Read at news.google.comThe GLP-1 Capacity Squeeze